Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Enlargement Clear all
Withdrawn Phase 1Phase 2 Interventional

Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy

NCT00281255
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiomyopathy, Dilated, Heart Diseases, Heart Failure, Congestive
Interventions
Allopurinol, Dobutamine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 26, 2026, 10:36 AM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction

NCT03533517
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Dilated
Interventions
AccuCinch® Ventricular Restoration
Device
Lead sponsor
Ancora Heart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 26, 2026, 10:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Refining Information Technology Support for Genetics in Medicine

NCT01225978
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
Interventions
GeneInsight Clinic (GIC)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 26, 2026, 10:36 AM EDT
Completed No phase listed Observational

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NCT00074880
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 10:36 AM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 26, 2026, 10:36 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Not applicable Interventional

EMPower: Electronic Media Powering Positive Health Changes in Youth

NCT02444689
View directory record Official record
Conditions
Hypertension, Prehypertension, Overweight, Obesity, Hypertrophy, Left Ventricular
Interventions
Electronic Media Application, Standard of care education
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 22 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 26, 2026, 10:36 AM EDT
Not listed Phase 1 Interventional

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

NCT02293603
View directory record Official record
Conditions
Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Allogeneic Cardiosphere-Derived Cells (CDCs)
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 26, 2026, 10:36 AM EDT
Terminated Phase 3 Interventional Results available

Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

NCT00608140
View directory record Official record
Conditions
Mitral Valve Insufficiency, Heart Failure
Interventions
Surgical mitral valvuloplasty with placement of annular ring (SMVR), Optimal medical therapy (OMT)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 26, 2026, 10:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

NCT07606274
View directory record Official record
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose
Genetic
Lead sponsor
Nuevocor Pte. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 26, 2026, 10:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

NCT03327623
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

NCT04349072
View directory record Official record
Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 26, 2026, 10:36 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

NCT01199211
View directory record Official record
Conditions
Left Ventricular Hypertrophy
Interventions
Exercise training, women, marathon
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 26, 2026, 10:36 AM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Ninerafaxstat 200mg MR, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 26, 2026, 10:36 AM EDT
Completed No phase listed Observational

Resynchronization Therapy in Young Patients With and Without CHD

NCT00208806
View directory record Official record
Conditions
Dilated Cardiomyopathy, Pediatric
Interventions
congestive heart failure patients
Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Not applicable Interventional

PITA-HF: Feasibility, Safety, and Tolerability

NCT04159454
View directory record Official record
Conditions
Heart Failure, Dilated Cardiomyopathy
Interventions
PITA
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 26, 2026, 10:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Optimized Biventricular Pacing Allograft Recipients

NCT01290822
View directory record Official record
Conditions
Dilated Cardiomyopathy, Ischemic Cardiomyopathy
Interventions
BiVP, AAI Pacing
Device
Lead sponsor
Henry M. Spotnitz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

NCT02842242
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
Interventions
MYK-461
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Phase 4 Interventional

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

NCT00139555
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 26, 2026, 10:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 26, 2026, 10:36 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 26, 2026, 10:36 AM EDT
Terminated Not applicable Interventional Results available

Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)

NCT01478087
View directory record Official record
Conditions
Cardiomyopathy, Dilated
Interventions
Mysorba
Device
Lead sponsor
Asahi Kasei Medical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 26, 2026, 10:36 AM EDT
Completed No phase listed Observational

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

NCT03043209
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Genetic Disease, Gene Product Sequence Variation
Interventions
Genomic sequencing
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 26, 2026, 10:36 AM EDT